Giant cell myocarditis following COVID-19 successfully treated by immunosuppressive therapy.
Afsaneh AmiriGolnaz HoushmandSepideh TaghaviMonireh KamaliMona FarajiAhmad AminPublished in: Clinical case reports (2022)
It has been shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by coronavirus disease 2019 (COVID-19), can lead to multi-organ impairment including cardiac involvement and immunological problems. Acute myocarditis is one of serious and fatal complications of COVID-19. In this case report, we present a 46-year-old lady with a history of lichen planus dermatitis who has developed a rapidly progressive heart failure after an episode of COVID-19. The pathologic examination of her endomyocardial biopsy specimens was compatible with GCM, and she was successfully treated with a combined immunosuppressive therapy regimen.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- heart failure
- case report
- giant cell
- multiple sclerosis
- mental health
- neoadjuvant chemotherapy
- lymph node
- bone marrow
- intensive care unit
- stem cells
- respiratory failure
- hepatitis b virus
- smoking cessation
- cell therapy
- mesenchymal stem cells
- replacement therapy
- acute heart failure
- cardiac resynchronization therapy